Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07680686
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.

Key Dates

First listed
Jul 2, 2026
Start date
Jul 14, 2026
Status verified
Aug 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
52 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Ubrogepant-Part 1-Dose A
    Participants will receive a single oral dose A of ubrogepant on Day 1 under fasting conditions.
  • Experimental: Ubrogepant-Part 1-Dose B
    Participants will receive a single oral dose B of ubrogepant on Day 1 under fasting conditions.
  • Experimental: Ubrogepant-Part 2-Dose C
    Participants will receive a single oral dose C of ubrogepant on Day 1 under fasting conditions.
  • Experimental: Ubrogepant-Part 2-Dose D
    Participants will receive a single oral dose D of ubrogepant on Day 1 under fed conditions.

Primary Outcome Measure

Number of Participants Experiencing Adverse Events [ Time Frame: Up to approximately 33 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 282727GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies